Aptamers in nanostructure-based electrochemical biosensors for cardiac biomarkers and cancer biomarkers: A review
M Negahdary - Biosensors and Bioelectronics, 2020 - Elsevier
Heart disease (especially myocardial infarction (MI)) and cancer are major causes of death.
Recently, aptasensors with the applying of different nanostructures have been able to …
Recently, aptasensors with the applying of different nanostructures have been able to …
Serum markers of hepatocellular carcinoma
G Malaguarnera, M Giordano, I Paladina… - Digestive diseases and …, 2010 - Springer
Background The hepatocellular carcinoma is one of the most common malignant tumors and
carries a poor survival rate. The management of patients at risk for developing HCC remains …
carries a poor survival rate. The management of patients at risk for developing HCC remains …
Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker
T Nakatsura, Y Yoshitake, S Senju, M Monji… - Biochemical and …, 2003 - Elsevier
With the global pandemic of hepatitis B and C infections, the incidence of Hepatocellular
carcinoma (HCC) is rapidly increasing world wide. We identified glypican-3 (GPC3), a novel …
carcinoma (HCC) is rapidly increasing world wide. We identified glypican-3 (GPC3), a novel …
Des–Gamma Carboxyprothrombin Can Differentiate Hepatocellular Carcinoma From Nonmalignant Chronic Liver Disease in American Patients
Mortality due to hepatocellular carcinoma (HCC) has not improved over the last 20 years.
This is in part due to the poor performance of available tumor markers leading to delays in …
This is in part due to the poor performance of available tumor markers leading to delays in …
[HTML][HTML] Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection
Z Cheng, P Yang, S Qu, J Zhou, J Yang, X Yang, Y Xia… - Hpb, 2015 - Elsevier
Background Intrahepatic recurrence is a significant problem for patients who have
undergone a hepatic resection for hepatocellular carcinoma (HCC). The objective of the …
undergone a hepatic resection for hepatocellular carcinoma (HCC). The objective of the …
Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC
H Toyoda, T Kumada, T Tada, Y Sone, Y Kaneoka… - Liver cancer, 2015 - karger.com
Background: The effectiveness of tumor markers in evaluating outcomes of patients with
hepatocellular carcinoma (HCC) remains to be clarified. Summary: The usefulness of the …
hepatocellular carcinoma (HCC) remains to be clarified. Summary: The usefulness of the …
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers
CM Sturgeon, MJ Duffy, BR Hofmann… - Clinical …, 2010 - academic.oup.com
Abstract Background: Updated National Academy of Clinical Biochemistry Laboratory
Medicine Practice Guidelines for the use of tumor markers in the clinic have been …
Medicine Practice Guidelines for the use of tumor markers in the clinic have been …
Hepatocellualar carcinoma serum markers
G Bertino, A Ardiri, M Malaguarnera… - Seminars in …, 2012 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in some
areas of the world. In most cases, HCC is diagnosed at a late stage. Therefore, the …
areas of the world. In most cases, HCC is diagnosed at a late stage. Therefore, the …
[HTML][HTML] Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma
PP Song, JF Xia, Y Inagaki, K Hasegawa… - World journal of …, 2016 - ncbi.nlm.nih.gov
The prevalence of hepatocellular carcinoma (HCC) worldwide parallels that of persistent
infection with the hepatitis B virus (HBV) and/or hepatitis C virus (HCV). According to …
infection with the hepatitis B virus (HBV) and/or hepatitis C virus (HCV). According to …
Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
YE Chon, J Cheon, H Kim, B Kang, Y Ha… - Cancer …, 2023 - Wiley Online Library
Background Since atezolizumab plus bevacizumab (ATE+ BEV) regimen for patients with
unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data …
unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data …